Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV pp65-specific T-cell therapy after allogeneic stem cell transplantation
NL-OMON24017Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2011
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytomegalovirus pp65-specific cytotoxic t lymphocytes in cytomegalovirus disease (CMV), sponsored by Leiden University Medical Center. Primary endpoint: Safety. Started Nov 2011; status: recruiting.
02
Drugs
cytomegalovirus pp65-specific cytotoxic t lymphocytes
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on NL-OMON24017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24017.